FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. firmnews.title_view.
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients - AIM at Melanoma Foundation
Merck's Keytruda gets boost in kidney and head and neck cancer | pharmaphorum
Promega collaborate with Merck to develop MSI CDx for use with Keytruda
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced The Risk Of Distant Metastasis Or Death By 40% Compared Versus Placebo As Adjuvant Treatment In Resected, High-Risk Stage III Melanoma 2023 - EORTC
Keytruda Meets Trial Goals for Non-Small Cell Lung Cancer Treatment | LCFA
Merck's Keytruda Wins Approval for Yet Another Lung Cancer Indication | BioSpace
Pharma News | Merck, Sanofi, GSK, Hinova, Endogena, Amylyx
Hummingbird Bioscience collaborates with Merck for a clinical trial on HMBD-002, our anti-VISTA antibody, in combination with KEYTRUDA®
Merck launches DTC campaign for Keytruda - MM+M - Medical Marketing and Media
Asco 2018 – Merck's dominance leaves rivals scrabbling for subsets | Evaluate
Merck & Co axes Keytruda lung cancer niche amid FDA crackdown | pharmaphorum
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement In Disease-Free Survival Versus Placebo As Adjuvant Treatment For Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless Of PD-L1 Expression 2023 - EORTC
Merck has high Keytruda hopes outside U.S., but Q1 details sparse | Fierce Pharma
Merck's Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial | BioSpace
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma ...
FDA Approves Merck's KEYTRUDA for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node | World Pharma Today
FDA Approves Combining Merck's Keytruda With Chemotherapy in Lung Cancer Patients - WSJ
Merck, Moderna detail potential skin cancer vaccine progress | AP News
FDA Approves Mercks KEYTRUDA® for Patients with Recurrent or Metastatic Head and Neck Cancer | World Pharma Today
Keytruda wins second place in the race to approval for neo-adjuvant NSCLC - Clinical Trials Arena
Merck & Co's Keytruda rejected by UK NICE in advanced kidney cancer | S&P Global Market Intelligence
Pembrolizumab - Wikipedia
